|
Monday 13th June 2022 |
Text too small? |
Comvita now forecasts that its full year reported EBITDA is expected to be in a range of $28.5M –$30.0M (previous guidance operating EBITDA $27M – $30M). For clarity, this new range includes Comvita absorbing the impact of previously disclosed one off M&A costs of circa $1M. Comvita is also forecasting double digit growth in Net Profit after Tax for the full year versus the prior corresponding period.
Commenting David Banfield “I am delighted with the momentum that we are experiencing in the business and the ongoing resilience of our focused business model. Consumers continue to choose premium solutions from Comvita as a key part of helping to build natural immunity. This updated guidance is particularly encouraging given the material disruption to offline trade in mainland China through the last quarter and is testament to the quality of our team around the world and at home in Aotearoa, New Zealand”.
Ends.
Comvita full year guidance update – FY22
No comments yet
GTK - Gentrack's Veovo Acquires Dubai Technology Partners
SML - Additional information following Bright Dairy announcement
April 30th Morning Report
Rua Bioscience Market Update
FSF - Fonterra announces interim leadership changes
April 29th Morning Report
NZK - Blue Endeavour Pilot Farm and Wellboat Update
TRU - FY 31 March 2026 Revenue and Results Guidance Achieved
FBU - Fletcher Building sale of Fletcher Reinforcing and Wire
April 28th Morning Report